Valuation: NetraMark Holdings Inc.

Market Cap 64.35M 46.39M 40.05M 37.57M 34.22M 4.44B 65.24M 440M 173M 2.22B 174M 170M 7.39B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 64.35M 46.39M 40.05M 37.57M 34.22M 4.44B 65.24M 440M 173M 2.22B 174M 170M 7.39B EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week-4.17%
Current month-13.75%
1 month-13.75%
3 months-21.59%
6 months-32.35%
Current year-37.27%
1 week 0.64
Extreme 0.64
0.72
1 month 0.64
Extreme 0.64
0.85
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.98
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Date Insider Type Main position Quantity % Market Cap.
4/13/26 Tax

Chairperson

434,178 0.4686%
2/19/26 Option

Executive/Senior Manager

116,250 0.1354%
2/19/26 Other

Executive/Senior Manager

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%-4.17%-58.43%+187.50% 46.37M
-3.04%-5.08%-7.11%+51.59% 3,679B
-0.86%-1.53%-0.85%+1,119.43% 418B
-3.19%-5.16%+91.62%+173.92% 91.73B
-0.42%-2.54%-9.20%+46.82% 89.45B
-1.96%+0.37%-33.92%-2.57% 80.71B
-2.04%+4.05%-32.62%+202.48% 74.69B
-2.16%-4.72%+3.90%+74.98% 46.17B
-2.39%+4.26%-6.40%-14.57% 41.06B
-4.03%-8.58%+117.62%+289.59% 36.58B
Average -1.53%+1.23%+6.46%+212.92% 455.73B
Weighted average by Cap. -2.71%-0.32%-4.36%+155.02%

Financials

2026 *2027 *
Net sales 401K 289K 250K 234K 213K 27.64M 406K 2.74M 1.08M 13.85M 1.09M 1.06M 46.06M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
26-08-17 CA$0.6900 +1.47% 115,000
26-08-14 CA$0.6800 +3.03% 11,638
26-08-13 CA$0.6600 -1.49% 26,500
26-08-12 CA$0.6700 -4.29% 5,500
26-08-11 CA$0.7000 -2.78% 14,100

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock